• Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (as monotherapy or in combination with rituximab or obinutuzumab or with bendamustine and rituximab).
• CLL/small lymphocytic leukemia in patients with the 17p deletion (as monotherapy or in combination with rituximab or obinutuzumab or with bendamustine and rituximab).
• Waldenström’s macroglobulinemia (as monotherapy or in combination with rituximab).
• Chronic graft-versus-host disease after failure of 1 line of systemic therapy.

Contraindicated in:

• Severe hepatic impairment
• Total bilirubin level >3 times upper limit of normal (ULN) (unless due to nonhepatic cause or Gilbert's syndrome) (for chronic graft-versus-host disease)
• OB: Pregnancy
• Lactation: Lactation.

Use Cautiously in:

• Mild or moderate hepatic impairment
• Surgical procedures (if possible withhold for 3–7 days pre- and postoperatively)
• Cardiac risk factors, acute infections, history of cardiac arrhythmias (↑ risk of cardiac arrhythmias)
• Women and men of reproductive potential
• Pedi: Safety and effectiveness not established in children.

CV: hypertension, peripheral edema, atrial fibrillation/flutter, HF, SUDDEN CARDIAC DEATH, VENTRICULAR ARRHYTHMIAS.

Derm: rash.

GI: abdominal pain, constipation, diarrhea, vomiting, HEPATOTOXICITY.

GU: RENAL FAILURE.

Hemat: thrombocytopenia, anemia, BLEEDING, NEUTROPENIA.

Metab: ↓appetite.

MS: musculoskeletal pain.

Neuro: fatigue, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML), STROKE, transient ischemic attack.

Resp: dyspnea.
Misc: infection, MALIGNANCY, tumor lysis syndrome.

Drug-Drug:

• Strong CYP3A inhibitors, including clarithromycin, cobicistat, conivaptan, diltiazem, idelalisib, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, and ritonavir, significantly ↑ levels and risk of toxicity; avoid concurrent use. If short-term use of strong CYP3A inhibitors is necessary, ibrutinib may be temporarily interrupted.
• Moderate CYP3A inhibitors, including aprepitant, cimetidine, ciprofloxacin, clotrimazole, crizotinib, cyclosporine, dronedarone, erythromycin, fluconazole, fluvoxamine, imatinib, or verapamil, ↑ levels and the risk of toxicity; if concurrent therapy is necessary, ↓ ibrutinib dose in patients with mantle cell lymphoma, marginal zone lymphoma, CLL/small lymphocytic leukemia, or Waldenström’s macroglobulinemia; in patients with chronic graft-versus-host disease, ibrutinib dose may be modified if adverse reactions develop.
• Posaconazole and voriconazole↑ levels and the risk of toxicity; if voriconazole is necessary, ↓ ibrutinib dose; if posaconazole is necessary, dose of ibrutinib may need to be ↓ based on dose of posaconazole used.
• Strong CYP3A inducers, including carbamazepine, enzalutamide, phenytoin, and rifampin, significantly ↓ levels and effectiveness; avoid concurrent use.
• Concurrent use of antiplatelet agents or anticoagulants↑ risk of bleeding.

Natural-Natural Products:

• St. John's wort may ↓ levels and effectiveness; avoid concurrent use.

Natural-Food Products:

• Grapefruit juice or Seville oranges↑ levels and the risk of toxicity, avoid concurrent ingestion.

(Generic available)

• Capsules: 70 mg; 140 mg;
• Tablets: 140 mg; 280 mg; 420 mg;
• Oral suspension: 70 mg/mL;

Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Waldenström’s Macroglobulinemia

• PO (Adults): 420 mg once daily until disease progression or unacceptable toxicity; if given with rituximab or obinutuzumab, administer ibrutinib before the rituximab or obinutuzumab when given on the same day; Concurrent use of moderate CYP3A inhibitors: 280 mg once daily until disease progression or unacceptable toxicity; Concurrent use of posaconazole suspension (100 mg once daily, 100 mg twice daily, or 200 mg twice daily), or voriconazole 200 mg twice daily: 140 mg once daily until disease progression or unacceptable toxicity; Concurrent use of posaconazole suspension (200 mg 3 times daily or 400 mg twice daily), posaconazole IV 300 mg once daily, or posaconazole delayed-release tablets 300 mg once daily: 70 mg once daily until disease progression or unacceptable toxicity;Concurrent use of other strong CYP3A inhibitors: Avoid concurrent use.

Chronic Graft-Versus-Host Disease

• PO (Adults and Children 12 yr): 420 mg once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity; Concurrent use of moderate CYP3A inhibitors: 420 mg once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity; Concurrent use of posaconazole suspension (100 mg once daily, 100 mg twice daily, or 200 mg twice daily) or voriconazole 200 mg twice daily: 280 mg once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity; Concurrent use of posaconazole suspension (200 mg 3 times daily or 400 mg twice daily), posaconazole IV 300 mg once daily, or posaconazole delayed-release tablets 300 mg once daily: 140 mg once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity;Concurrent use of other strong CYP3A inhibitors: Avoid concurrent use.
• PO (Children 1–11 yr): 240 mg/m² (max = 420 mg) once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity (oral suspension should be used if body surface area [BSA] 0.7 m²; capsule, tablets, or oral suspension can be used if BSA >0.7 m²); Concurrent use of moderate CYP3A inhibitors: 240 mg/m² (max = 420 mg) once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity (oral suspension should be used if BSA 0.7 m²; capsule, tablets, or oral suspension can be used if BSA >0.7 m²); Concurrent use of voriconazole suspension 9 mg/kg twice daily: 160 mg/m² once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity (oral suspension should be used if BSA 0.7 m²; capsule, tablets, or oral suspension can be used if BSA >0.7 m²); Concurrent use of posaconazole: 80 mg/m² once daily until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity (oral suspension should be used if BSA 0.7 m²; capsule, tablets, or oral suspension can be used if BSA >0.7 m²);Concurrent use of other strong CYP3A inhibitors: Avoid concurrent use.

Imbruvica

• Binds to and inactivates Bruton’s tyrosine kinase (BTK). Inhibits malignant B-cell proliferation. A deletion in chromosome 17 (17p deletion) is associated with poor responses to standard treatment for CLL.

• Decreased progression of and improved survival with CLL/small lymphocytic leukemia.
• Decreased progression of Waldenström’s macroglobulinemia.
• Reduced severity of chronic graft-versus-host disease.

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 97.3%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A isoenzymes. One minor metabolite has antineoplastic activity. Metabolites are mostly eliminated in feces (80%), <10% excreted in urine.

Half-life: 4–6 hr.

(response)

†Median time to response.

• Explain purpose and side effects of ibrutinib to patient. Instruct patient to take ibrutinib as directed, at the same time each day. Take missed doses as soon as remembered on same day and return to normal schedule; do not take extra capsules to make up for missed dose. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
• Caution patient to avoid grapefruit, grapefruit juice, and Seville oranges during therapy; may increase amount of ibrutinib in blood.
• Advise patient to maintain adequate hydration during therapy to prevent renal failure.
• Advise patient to monitor BP at home especially if history of hypertension.
• Instruct patient to notify health care professional if signs and symptoms of infection, tumor lysis syndrome, or bleeding (blood in stools or black stools, pink or brown urine, unexpected or uncontrollable severe bleeding, vomiting blood or vomit that looks like coffee grounds, coughing up blood or blood clots, increased bruising, dizziness or weakness, confusion, change in speech, persistent headache) occur.
• Instruct patient to notify health care professional if signs and symptoms of HF (shortness of breath, swelling, weight gain, fatigue) or symptoms of cardiac arrhythmias (palpitations, light-headedness, feeling faint, chest pain) occur.
• Inform patient of risk of other types of cancer including skin cancer.
• Advise patient of common side effects: low blood platelet count, diarrhea, low white blood cell count, low red blood cell count, fatigue, muscle and bone pain, swelling legs and feet, upper respiratory tract infection, nausea, bruising, shortness of breath, constipation, rash, stomach pain, vomiting, decreased appetite. Instruct patient to notify health care professional if diarrhea is persistent.
• Advise patient to notify health care professional of medication regimen before treatment or surgery.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products, especially St. John's wort, being taken, as they can affect the way ibrutinib works; consult with health care professional before taking other medications.
• May cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during and for 1 mo following end of therapy; avoid breastfeeding during therapy and for 1 wk after last dose. Advise patient to notify health care professional if pregnancy is suspected or if breastfeeding.

eye- BROO-ti-nib